JPWO2007114499A1 - Anti-fat accumulation composition - Google Patents

Abstract

An anti-fat accumulating composition containing a sugar alcohol and an oligosaccharide in a weight ratio of 1: 3 to 1:20, preferably 1: 7 to 1:10. For example, xylitol is preferably used as the sugar alcohol. For example, palatinose is preferably used as the oligosaccharide. The anti-fat accumulation composition of the present invention is excellent in taste and safety, and has high activity and high certainty in the anti-fat accumulation effect.

Description

  The present invention relates to a composition having an anti-fat accumulation effect.

The prevention and treatment of obesity is a very important issue in maintaining and improving health. Obesity causes type 2 diabetes, hypertension, hyperlipidemia and the like. Furthermore, these diseases are also basic diseases such as stroke and ischemic heart disease. Currently, these diseases are understood as a series of metabolic abnormalities based on insulin resistance caused by obesity. Among them, the number of diabetic patients, including the diabetes reserve army, has increased by 2.5 million over the past five years to 16.2 million, and it is now no exaggeration to call it national disease. Thus, since obesity is related to major diseases, the spread and increase of obesity is gaining attention in developed countries. The same is true in developing countries, and it has already been estimated that the prevalence and growth of obesity will dramatically increase the prevalence of type 2 diabetes over the next decade. Recent findings suggest that increased postprandial blood glucose and insulin levels are risk factors for diabetes, heart disease and cancer, and reducing postprandial blood glucose and insulin levels is useful in preventing and treating these diseases. (ILCI JAPAN Saccharide Research Group, International Conference Lecture “International Symposium Carbohydrates and Health”, Kenshin Co., Ltd., published December 2003). The three major causes of death in Japan are cancer, heart disease, and stroke. One of the causes of cardiovascular disease that combines heart disease and stroke is “arteriosclerosis”. Cholesterol is famous as a risk factor for “arteriosclerosis”, but recent studies have shown that obesity (especially visceral fat) causes various lifestyle-related diseases and is more susceptible to arteriosclerosis. For these reasons, prevention of obesity, which can be a factor causing various diseases, is also useful for healthy individuals.
So far, drugs for suppressing obesity include gastrointestinal lipase inhibitors (Sjostrom L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HP, Krempfoltrent, and Randomized placebo-control. of weight regain in obese patients. European Multicentre Orlistat Study Group., Lancet, 352, pp. 167-172 (1998)), appetite suppressant (Tomoaki Saito, Hiroshi Mitsubayashi, Masahiro Mitsubayashi Effects on blood pressure, carbohydrate metabolism and lipid metabolism, medical care and new 32 (9), pp.1653-1660 (1995)), and as a food for suppressing obesity, a composition containing protein, lipid and carbohydrate in a specific ratio (Japanese Patent No. 3545760) or Hydroxycitric acid (Kentaro Onomura, Hirotaka Tomi, Ryuichi Otsuka, Keiko Kawabata, Effects of long-term intake of jelly drink containing garcinia extract on human body fat mass, Research on health and nutritional foods, 3 (4), pp.23- 30 (2000)), capsaicin (KAWADA T, HAGIHARA K, IWAI K, Effects of capsaicin on lipid metabolism in rats, fed a high fat diet., J Nutr, 116 (12), p. Even if added to various foods and drinks Without impairing the sense, prolonged over it can be safely ingested anti-adiposity composition has been further desired.
Xylitol is a kind of sugar alcohol and is used as a substitute for sugar. Since xylitol is absorbed from non-insulin-mediated pathways, it has been shown that it does not increase blood glucose levels or insulin secretion (Geoffrey Liveey, Health potential of polyols as suger respirites, recycle citrus respirites. 16, pp 163-191 (2003)). In addition, an anti-cariogenic effect (as a sugar that is difficult to become caries, good for teeth, etc.) has been reported (Geoffrey Liveey, Health potent of polys as supra respiris, with empisis on low glycem pir. Pp163-191 (2003)). Further improvement of osteoporosis (Mattila PT, Svanberg MJ, Jamsa T, Knuttila ML, Improve bone biochemical properties in xylitol-fed aged rats., 92, p. 95, p. 1). M Niemela, O Pihakari, T Pokka, M Uhari, M Uhari, Pacifier as a Risk Factor for Acti tis Media, A: 48 Randomized, Control Trial. ) Is also reported . Thus, there is interest in a variety of potential health benefits. However, no fat accumulation inhibitory effect has been reported yet.
Palatinose is a type of oligosaccharide. It is also called isomaltulose and is used for sweeteners. Orally ingested palatinose is degraded by isomaltase in the digestive tract. In addition, isomaltose, panose, isomaltotriose, etc. that are digested with isomaltase compete with the digestion of palatinose, and it is said that digestion and absorption are suppressed by ingestion of palatinose (Journal of Japanese Society of Nutrition and Food, 36 (3), pp. 169-173 (1983)). In addition, the degradation rate of palatinose is about 1/5 that of sucrose, which suppresses a rapid increase in blood glucose level and blood insulin concentration.
Furthermore, an effect of suppressing blood sugar elevation and an effect of suppressing fat accumulation when ingested together with a sugar that is decomposed and metabolized without using isomaltase such as sucrose or glucose has been reported (Japanese Patent Laid-Open No. 2004-315499). However, there are no reports on synergistic effects when combined with sugar alcohols such as xylitol.

An object of the present invention is to find an anti-fat accumulating composition having higher activity and superior taste and safety.
The present invention has been made to solve the above problems. In the nutrition composition for blood glucose level control shown in Japanese Patent No. 3545760, the present inventors consider that palatinose and / or trehalulose in carbohydrates are effective as one of the components that suppress the increase in blood sugar and the accumulation of body fat. In addition, other ingredients that exert an inhibitory effect on blood sugar elevation and fat accumulation in the nutritional composition for blood glucose level control were also intensively studied. As a result, it has been found that xylitol contained in the nutritional composition for blood glucose level control contributes to the exertion of the anti-fat accumulation effect in vivo.
Furthermore, the present inventors have found that a sugar alcohol such as xylitol, or a mixture in which a sugar alcohol and an oligosaccharide (for example, palatinose) are mixed at a certain ratio has an anti-fat accumulation effect, thereby completing the present invention. It was.
That is, the present invention
[1] An anti-fat accumulation composition containing a sugar alcohol,
[2] The composition for accumulating anti-fat according to the above [1], containing an oligosaccharide,
[3] The anti-fat accumulation composition according to [2], wherein the oligosaccharide is a hetero-oligosaccharide,
[4] The anti-fat accumulation composition according to [3], wherein the hetero-oligosaccharide is a sucrose structural isomer.
[5] The anti-fat accumulation composition according to any one of [2] to [4], wherein the sucrose structural isomer is palatinose,
[6] The composition for accumulating anti-fat according to any one of [2] to [5], which contains the sugar alcohol and the oligosaccharide in a weight ratio of 1: 3 to 1:20,
[7] The composition for accumulating anti-fat according to any one of [1] to [6], wherein the sugar alcohol is xylitol,
[8] A drug for preventing and / or treating fat accumulation, comprising as an active ingredient the composition for anti-fat accumulation according to any one of [1] to [7],
[9] A food and drink for fat accumulation prevention and / or treatment containing the anti-fat accumulation composition according to any one of [1] to [7],
[10] Production of a drug for preventing and / or treating fat accumulation or a food and drink for preventing and / or treating fat accumulation of the composition for accumulating fat according to any one of [1] to [7] Use for,
[11] A method for preventing and / or treating fat accumulation by administering the composition for anti-fat accumulation according to any one of [1] to [7],
Is to provide.
The composition for accumulating anti-fat of the present invention has an effect of suppressing accumulation of blood fat, body fat, visceral fat and subcutaneous fat, and therefore obesity, type 2 diabetes, hypertension, hyperlipidemia, stroke, imaginary It is useful for the prevention and / or treatment of blood heart disease and the like. That is, there is an advantage that an anti-fat accumulating composition that can be added to foods and drinks and pharmaceuticals and has excellent taste and safety can be easily provided.

FIG. 1 shows changes in the average body weight (g) of each group during the test period in Example 1. Mean value ± standard deviation (n = 9). Δ represents a control group, and ▪ represents an Xy1 group.
FIG. 2 shows the X-ray CT apparatus in Example 1 before the start of the test (6 days before the test start date), during the middle of the test (25 days after the test start date) and during the late test (53 days after the test start date). Changes in relative muscle mass (g / g body weight) and relative fat mass (g / g body weight) determined from the results are shown as percentages. Mean value ± standard deviation (n = 9). □ indicates a control group, and ■ indicates an Xy1 group. *: P <0.05 (Student t test).
FIG. 3 shows the relative fat mass (g / g body weight) of the testis, retroperitoneum, and mesentery at the time of necropsy (58 days after the test start date) in Example 1 as a percentage. Mean value ± standard deviation (n = 9). □ indicates a control group, and ■ indicates an Xy1 group. *: P <0.05 (Student t test).
FIG. 4 shows changes in the average body weight (g) of each group during the test period in Example 2. Mean value ± standard deviation (n = 6). Δ indicates a control group, and ● indicates a palatinose group.
FIG. 5 shows the relative fat mass (g / g body weight) around the testis and retroperitoneum at the time of necropsy (66 days after the test start date) in Example 2 as a percentage. Mean value ± standard deviation (n = 6). □ indicates a control group, and ■ indicates a palatinose group. **: p <0.01 (Student's t test).
FIG. 6 shows the transition of the average body weight (g) of each group during the test period in Example 3. Mean value ± standard deviation (n = 6). Δ represents a control group, and ◆ represents an Xy1 group. *: P <0.05 (Student t test).
FIG. 7 shows the X-ray CT apparatus of Example 3 before the start of the test (6 days before the test start date), during the middle of the test (28 days after the test start date) and during the late test (56 days after the test start date). Changes in relative muscle mass (g / g body weight) and relative fat mass (g / g body weight) determined from the results are shown as percentages. Mean value ± standard deviation (n = 6). □ indicates the Xy1 (−) group, and ■ indicates the Xy1 (+) group. *: P <0.05 (Student t test).
FIG. 8 shows the relative fat mass (g / g body weight) of the testis, retroperitoneum, and mesentery at the time of necropsy (60 days after the test start date) in Example 3 as a percentage. Mean value ± standard deviation (n = 6). □ indicates the Xy1 (−) group, and ■ indicates the Xy1 (+) group. **: p <0.01 (Student's t test)
FIG. 9 shows changes in the average body weight (g) of each group during the test period in Example 4. Mean value ± standard deviation (n = 6). □ indicates a control group, ◆ indicates a palatinose group, Δ indicates a low xylitol dose group, ▲ indicates a low combination dose group, ○ indicates a high xylitol dose group, and ● indicates a high combination dose group. *: Vs. Control group, p <0.05 (Tukey-Kramer multiple comparison test).
FIG. 10 shows the results of Example 4 before the start of the test (7 or 6 days before the test start date), during the middle of the test (28 or 29 days after the test start date), and late in the test (56 or 57 days after the test start date). The change in relative muscle mass (g / g body weight) and relative fat mass (g / g body weight) determined from the results of the X-ray CT apparatus is shown as a percentage. Mean value ± standard deviation (n = 6). *, **: vs. Control group, p <0.05, 0.01 (Tukey-Kramer multiple comparison test).
FIG. 11 shows the relative fat mass (g / g body weight) around the testis at the time of necropsy (60 days after the test start date) in Example 4 as a percentage. Mean value ± standard deviation (n = 6). **: vs. Control group, p <0.01 (Tukey-Kramer multiple comparison test).
FIG. 12 shows the relative fat amount (g / g body weight) of the retroperitoneum at the time of necropsy (60 days after the test start date) in Example 4 as a percentage. Mean value ± standard deviation (n = 6). *, **: vs. Control group, p <0.05, 0.01 (Tukey-Kramer multiple comparison test).
FIG. 13 shows the relative fat mass (g / g body weight) of the mesentery at the time of necropsy (60 days after the test start date) in Example 4 as a percentage. Mean value ± standard deviation (n = 6). *, **: vs. Control group, p <0.05, 0.01 (Tukey-Kramer multiple comparison test).

Hereinafter, the present invention will be described in detail. However, the present invention is not limited to the following preferred embodiments, and can be freely changed within the scope of the present invention.
Sugar alcohol is a general term for compounds having a structure in which an aldehyde group of sugar is reduced to become alcohol. When sugar alcohol is taken orally, about half is absorbed into the body, and the rest reaches the large intestine and is used for fermentation of intestinal bacteria (Geoffrey Liveey, Health potential of polyols as sugar repulcers, with emphasis on low glycemic properties., Nutrition Research Reviews., 16, pp 163-191 (2003)). In addition, even if it is absorbed, it is attracting attention as a low-calorie sweetener because it has a different metabolic pathway from sugar and is less likely to become energy.
The sugar alcohol used in the anti-fat accumulation composition of the present invention is not particularly limited, and examples thereof include xylitol, sorbitol, maltitol, erythritol, lactitol, mannitol, and palatinit (reduced palatinose). .
Among them, xylitol can surely obtain a synergistic anti-fat accumulation effect only by adding a small amount to an oligosaccharide (for example, palatinose), and has a refreshing sweet taste and a refreshing aftertaste is expected. It is preferably used because it can be used.
These sugar alcohols may be any of naturally-derived products, chemically synthesized products, synthetic products by enzymes and microorganisms, and / or foods containing a large amount thereof. These sugar alcohols can be used alone or in combination of two or more.
Xylitol is also a kind of polyhydric alcohol, and is also referred to as xylo-pentitol or xylit, trans, clinit, eutrit, and chirit. Molecular weight 152.146, Cas. No. 87-99-0, which is used as a tonic, a carbohydrate metabolizing agent, a nutrient, a sugar substitute, and the like. It has been found that many plants such as strawberries, raspberries and cauliflower contain very small amounts. It is also produced commercially from the remainder of hardwood and birch wood. Like fructose, xylitol is very soluble in water and can withstand heating and freezing. Xylitol has almost the same sweetness as fructose and is refreshing in aqueous solution. Its sweetness is reduced by heating and addition of acidity (John D. Brunzell, Use of fructose, sorbitol, or xylitol as a wetter in dibetes melitus., J. The American Diet. 1978)). Since the heat of dissolution in water is −36.6 cal / g, a cool feeling can be enjoyed when taken orally. Xylitol taken orally taken and absorbed is converted into D-xylulose by xylitol dehydrogenase and metabolized to carbon dioxide and water by the pentose phosphate circuit, etc., so that it hardly affects the blood glucose level. The energy conversion factor is 3 kcal / g (Geoffre Liveies, Health potential of polyols as suger replacers, with emphasis on low glymic properties. Moreover, although it is very weak, it is reported that it has alpha-glucosidase inhibition (patent 2790610). Therefore, it is difficult to increase insulin secretion and blood glucose level after ingestion. The glycemic index and the index of insulin secretion, which are indicators of blood glucose level and insulin secretion after ingestion of xylitol, are 13 and 11, which are very low compared to glucose 100 and 100 or sucrose 65 and 43. It is also said to have anti-cariogenic properties because of its low utilization efficiency in carious microorganisms such as mutans bacteria (Geoffrey Livery, Health potent of polyols, with emphasis on low bloody. Nutrition Research Reviews., 16, pp 163-191 (2003)). Further improvement of osteoporosis (M Niemela, O Pihakari, T Pokka, M Uhari, M Uhari, Pacifier as a Risk Factor for AccuRI, Co., Ltd., CRI. 483-488 (2000)), prevention of otitis media (Journal of Japanese Society of Nutrition and Food, 36 (3), pp.169-173 (1983)). In this way, it has characteristics such as suppression of blood sugar elevation, low digestibility, excellent caries resistance and osmotic pressure, and is interested in various potential health benefits. However, no antifat accumulation effect has been reported.
The type of the oligosaccharide used in the anti-fat accumulation composition of the present invention is not limited, and may be either a homo-oligosaccharide or a hetero-oligosaccharide.
Examples of homo-oligosaccharides include isomaltose, cordobiose, nigerose, isomaltotriose, isomalttetraose, panose, malto-oligosaccharide, xylooligosaccharide, inulo-oligosaccharide, isomalt-oligosaccharide, high-maltotriose syrup, cellooligosaccharide, trehalose, Examples include gentiooligosaccharide, panose, and nigerooligosaccharide.
Examples of hetero-oligosaccharides include palatinose, fructooligosaccharide, galactooligosaccharide, transfer galactooligosaccharide, soybean oligosaccharide, raffinose, palatinose syrup (syrup based on trehalulose and palatinose), palatinose oligosaccharide, dairy oligosaccharide, glucosyl sucrose, Examples include lactulose, trehalulose, and apple oligosaccharide. Among them, sucrose structural isomers such as palatinose and trehalulose can be preferably used.
In addition, these oligosaccharides may be any of naturally derived products, chemically synthesized products, synthetic products by enzymes and microorganisms, and / or foods containing a large amount thereof. Moreover, these oligosaccharides can be used individually or in combination of 2 or more types.
Among the oligosaccharides mentioned above, palatinose can surely obtain a synergistic anti-fat accumulation effect when a small amount of sugar alcohol (for example, xylitol) is added, and the digestive absorption after meals is slow. It can be preferably used in that it can provide an effect of suppressing the increase in blood glucose due to the fact that it is absorbed 100%.
Palatinose is a disaccharide in which glucose and fructose molecules are α-1,6-linked, and is a structural isomer of sucrose. 6-O- (α-D-Glucopyranosyl) -D-fructose or isomaltulose, Also called isomaltulose. Molecular weight 342.2297, Cas. No. 13718-94-0, which is used as a sweetener. Very small amounts of honey and sugar cane. It can also be produced by allowing α-glucosyltransferase derived from Protaminobacter rubrum to act on sucrose to transfer α-1,2 bond to α-1,6 bond. The sweetness of palatinose is similar to that of sucrose, but the sweetness is about half that of sucrose. It is also said to have anti-cariogenic properties because it is not a substrate for insoluble glucan synthesis by cariogenic microorganisms such as S. mutans, and competitively suppresses insoluble glucan synthesis from sucrose (Nakakuki T, Trends). in Glycoscience and Glycotechnology, 15 (82), pp. 57-64 (2003)). Orally ingested palatinose is degraded by isomaltase in the digestive tract. In addition, isomaltose, panose, isomaltotriose, etc. that are digested with isomaltase compete with the digestion of palatinose, and it is said that digestion and absorption are suppressed by ingestion of palatinose (Journal of Japanese Society of Nutrition and Food, 36 (3), pp. 169-173 (1983)). The calorie is 4 kcal / g. The degradation rate of palatinose is about 1/5 that of sucrose, which suppresses rapid increases in blood glucose level and blood insulin concentration. On the other hand, the mechanism of obesity includes a mechanism in which lipoprotein lipase in adipose tissue is activated by insulin, and neutral fat in blood is quickly taken into the adipose tissue and accumulated as body fat. Since palatinose is slow in digestion and absorption after ingestion and has low insulin secretion stimulation, it does not increase the activity of lipoprotein lipase, and at the same time, ingested fat is unlikely to be taken into the adipose tissue. As a result, an effect of suppressing fat accumulation appears (palatinose catalog, Mitsui Sugar Co., Ltd.). Furthermore, an effect of suppressing blood sugar elevation and an effect of suppressing fat accumulation when ingested together with a sugar that is decomposed and metabolized without using isomaltase such as sucrose or glucose has been reported (Japanese Patent Laid-Open No. 2004-315499). However, there are no reports on synergistic effects when combined with sugar alcohols such as xylitol.
It has been confirmed by an in vivo body fat accumulation test that the anti-fat accumulation composition of the present invention is useful as a composition effective for the prevention and / or treatment of fat accumulation.
In the nutrition composition for blood glucose level control shown in Japanese Patent No. 3545760, the present inventors consider that palatinose and / or trehalulose in carbohydrates are effective as one of the components that suppress the increase in blood sugar and the accumulation of body fat. As reported, the present inventors have also intensively studied other components that exert an effect of increasing blood glucose and anti-fat accumulation in the nutritional composition for controlling blood glucose level.
First, xylitol was partially replaced with sucrose in the purified feed for mice and rats to prepare xylitol-added purified feed, and a test was conducted in which mice were freely ingested for 2 months. As a result, the mice fed with the purified diet supplemented with xylitol had a significantly lower relative fat content at necropsy than the mice fed the purified diet without added xylitol. This suggested that xylitol has an anti-fat accumulation effect.
In addition, a test was conducted in which rats were allowed to freely ingest for 2 months using a control diet in which 40% sucrose in the purified feed for mice and rats and a test diet to which palatinose was added instead of sucrose were added. As a result, the rats fed the test diet had a significantly lower relative fat content at necropsy than the rats fed the control diet. This proved the antifat accumulation effect of palatinose.
Furthermore, the degree of the anti-fat accumulation effect was compared between a feed containing palatinose and a feed containing a small amount of xylitol and a feed containing no xylitol. When xylitol was added to feed containing palatinose, the weight ratio of xylitol and palatinose was 1.0: 5.5 to 1.0: 15.6, and the amount of xylitol added was clearly much less than that of palatinose. Nevertheless, a more pronounced anti-fat accumulation effect was found in feed compositions containing xylitol. That is, it was shown that xylitol and palatinose had a synergistic effect on fat accumulation suppression.
Thus, sugar alcohols (xylitol, sorbitol, maltitol, erythritol, lactitol, mannitol, palatinite (reduced palatinose), etc.) or sugar alcohols and oligosaccharides (palatinose, isomaltose, cordobiose, nigerose, isomaltotriose, panose, iso Similarly, a mixture of maltotetraose and the like) can be expected to be effective as an anti-fat accumulation composition.
The anti-fat accumulation composition of the present invention has an effect of suppressing the accumulation of blood fat, body fat, visceral fat and subcutaneous fat, and is effective for obesity, complications of obesity, diabetes, syndrome X, and insulin resistance. Diseases based on abnormalities (such as hyperinsulinemia), hypertension, hyperlipidemia, arteriosclerosis, hyperuricemia, gout, fatty liver, cholelithiasis, respiratory diseases (such as sleep apnea syndrome, Pickwick syndrome) , Cardiovascular disease (stroke, ischemic heart disease, angina pectoris, myocardial infarction, congestive heart failure, generalized intravascular coagulation syndrome, cardiac hypertrophy, etc.), bone and joint disorders (osteoarthritis, lumbar spondylolisthesis) Application to prevention and / or treatment of infertility, menstrual abnormalities, uterine cancer, neurological diseases (such as sciatica), and chronic nephritis. That is, there is an advantage that an anti-fat accumulating composition that can be added to foods and drinks and pharmaceuticals and has excellent taste and safety can be easily provided.
The content of the sugar alcohol or oligosaccharide contained in the anti-fat accumulation composition of the present invention is not particularly limited because it varies depending on the form, dosage form, symptom, body weight, use, etc. In the composition for anti-fat accumulation of the present invention, the range is preferably from 0.8% (w / w) to 100% (w / w). A range of 0% (w / w) to 100% (w / w) is preferable. Sugar alcohol and oligosaccharide may be used alone or in combination. When used in combination, the sugar alcohol and oligosaccharide can be used in combination at any ratio, but from the viewpoint of the effect of the combined use, the weight ratio is preferably 1: 3 to 1:20, more preferably the weight ratio 1: 4 to It can be contained at 1:15, more preferably at a weight ratio of 1: 5 to 1:12, particularly preferably at a weight ratio of 1: 7 to 1:10.
If the weight ratio is 1: 5 to 1:12 (especially 1: 7 to 1:10), the effect of the combined use of the sugar alcohol and the oligosaccharide can be more reliably (in other words, between individuals to be ingested). The difference in effectiveness is small and can be obtained (with a small standard deviation).
In the present invention, the total intake amount of sugar alcohol and oligosaccharide is preferably 3 to 200 g, more preferably 7 to 160 g, and particularly preferably 14 to 130 g per person per day.
The number of intakes per day of the composition for accumulating anti-fat of the present invention is preferably 1 to 5 times, but can be appropriately changed according to symptoms and purposes. It can also be taken continuously such as by tube.
The proportion of oligosaccharide energy in the total amount of carbohydrate energy in the anti-fat accumulation composition of the present invention is preferably 60 to 80%.
The blending amount of the anti-fat accumulation composition of the present invention into a pharmaceutical product or food or drink varies depending on the form, dosage form, symptom, body weight, use, etc., and is not particularly limited, but is 0.01-100% (w / w) The content can be blended at a content of preferably 0.1 to 100% (w / w), more preferably 1.0 to 100% (w / w).
The daily intake of the pharmaceutical or food / drink of the anti-fat accumulation composition of the present invention varies depending on age, symptoms, body weight, use, etc., and is not particularly limited, but should be 0.1 to 10,000 mg / kg body weight. Preferably 1.0 to 5000 mg / kg body weight, more preferably 10.0 to 3500 mg / kg body weight.
The composition for accumulating anti-fat of the present invention can be used in the form of any medicine or food or drink. For example, it is expected to treat and / or prevent various inflammations by directly administering it as a pharmaceutical, or by directly ingesting it as a special-purpose food such as a food for specified health use or a nutritional functional food. In addition, various foods (milk, soft drinks, fermented milk, yoghurt, cheese, bread, biscuits, crackers, pizza crusts, prepared milk powder, liquid foods, for the sick, regardless of the form of liquid, paste, solid, powder, etc. Foods, nutritional foods, frozen foods, processed foods, and other commercially available foods).
The food containing the anti-fat accumulation composition of the present invention may be used by mixing water, protein, carbohydrates, lipids, vitamins, minerals, organic acids, organic bases, fruit juices, flavors and the like. it can. Examples of the protein include whole milk powder, skim milk powder, partially skimmed milk powder, casein, whey powder, whey protein, whey protein concentrate, whey protein isolate, α-casein, β-casein, κ-casein, β-lactoglobulin , Α-lactalbumin, lactoferrin, soy protein, chicken egg protein, meat protein and other animal and vegetable proteins, degradation products thereof; butter, milk minerals, cream, whey, non-protein nitrogen, sialic acid, phospholipid, lactose, etc. And various milk-derived components. It may contain peptides and amino acids such as casein phosphopeptide, arginine and lysine. Examples of the saccharide include saccharides, processed starch (in addition to dextrin, soluble starch, British starch, oxidized starch, starch ester, starch ether, etc.), dietary fiber, and the like. Examples of the lipid include animal oils such as lard, fish oil, etc., fractionated oils, hydrogenated oil, transesterified oil, etc .; palm oil, safflower oil, corn oil, rapeseed oil, coconut oil, fractionated oils thereof, Examples include vegetable oils such as hydrogenated oils and transesterified oils. Examples of vitamins include vitamin A, carotene, vitamin B group, vitamin C, vitamin D group, vitamin E, vitamin K group, vitamin P, vitamin Q, niacin, nicotinic acid, pantothenic acid, biotin, inositol, choline. Examples of minerals include calcium, potassium, magnesium, sodium, copper, iron, manganese, zinc, and selenium. Examples of the organic acid include malic acid, citric acid, lactic acid, and tartaric acid. In the production of foods and drinks containing the anti-fat accumulation composition of the present invention, these may be either synthetic products or products derived from natural products, and / or foods containing a large amount may be used as raw materials. These components can be used in combination of two or more. The form of food may be solid or liquid. It may be in the form of a gel.
When the anti-fat accumulation composition of the present invention is used as a pharmaceutical product, it can be administered in various forms. Examples of the form include oral administration such as tablets, capsules, granules, powders, syrups, etc., but other forms such as tube and intravenous injection may be used. These various preparations can be generally used in the pharmaceutical preparation technical field such as excipients, binders, disintegrants, lubricants, flavoring agents, solubilizers, suspension agents, coating agents, etc. as main ingredients according to conventional methods. It can be formulated using known adjuvants. Further, it may contain an appropriate amount of calcium. Further, an appropriate amount of vitamins, minerals, organic acids, sugars, amino acids, peptides, etc. may be added.
In addition, all prior art documents cited in the present specification are incorporated herein by reference.

上記表１は各試験食１００ｋｃａｌ当たりの配合量（ｇ）を示す。また、表１に記載の改変ＡＩＮ−９３Ｍとは、米国国立栄養研究所（ＡＩＮ）から１９９３年に発表されたマウスやラットにおける栄養研究用の標準精製飼料であるＡＩＮ−９３Ｍよりコーンスターチおよびショ糖を除いたものをいう。なお、ＡＩＮ−９３Ｍは成長期を過ぎた成熟動物用の標準精製飼料である。
（２）結果および考察
体重および平均摂取熱量：結果を第１図に示す。両群とも体重は順調に増加し、群間に有意な差は認められなかった。試験期間中の平均摂餌量（ｇ／ｂｏｄｙ，ｄａｙ）から以下の式（数式１：ＡＩＮ−９３Ｍ飼料および数式２：キシリトール添加ＡＩＮ−９３Ｍ飼料）により試験期間中の平均摂取熱量（ｋｃａｌ／ｂｏｄｙ，ｄａｙ）を算出したところ、対照群およびＸｙ１群でそれぞれ１２．７および１２．３ｋｃａｌ／ｂｏｄｙ，ｄａｙとなり、ほぼ同等であった。

相対筋肉量および相対脂肪量：結果を第２図に示す。Ｘ線ＣＴの結果から求めた相対筋肉量は試験開始前では差がなく、飼育期間の経過にしたがってＸｙ１群が対照群に比べて高い値を示す傾向にあった。試験後期では、Ｘｙ１群は対照群に比べて有意に（ｐ＜０．０５）高い値を示した。Ｘ線ＣＴの結果から求めた相対脂肪量は、試験開始前では差がなく、飼育期間の経過にしたがってＸｙ１群が対照群に比べて低い値を示す傾向にあった。試験後期では、Ｘｙ１群は対照群に比べて有意に（ｐ＜０．０５）低い値を示した。
剖検時の相対脂肪量：結果を第３図に示す。後腹膜および腸間膜の相対脂肪量は、Ｘｙ１群が対照群に比べて低い値を示す傾向にあった。精巣周囲の相対脂肪量は、Ｘｙ１群は対照群に比べて有意（ｐ＜０．０５）に低い値を示し、Ｘ線ＣＴ測定と同様の結果が得られた。
以上のように、体重増加および摂取熱量が同等であるにも関わらず、Ｘｙ１群は対照群に比べて脂肪蓄積量が有意に低いことが認められた。マウス・ラット用精製飼料の糖質の一部をＸｙ１に置換することによって、体脂肪の蓄積を抑制できることが明らかとなった。
［実施例２］（パラチノースの抗脂肪蓄積効果測定）
（１）材料および方法
ＳＤラット（雄性、４週齢入荷、６週齢試験開始、ｎ＝６／群）を群分けして、パラチノース群と対照群を設けた。ＡＩＮ−９３Ｇよりコーンスターチおよびショ糖を除いたもの（以下、改変ＡＩＮ−９３Ｇともいう）を６０％（ｗ／ｗ）、パラチノースを４０％（ｗ／ｗ）混合して４０％パラチノース添加ＡＩＮ−９３Ｇ飼料を作製し、これを試験食として与えた群をパラチノース群とした。対照群には改変ＡＩＮ−９３Ｇを６０％（ｗ／ｗ）、ショ糖を４０％（ｗ／ｗ）混合して作製した、４０％ショ糖添加ＡＩＮ−９３Ｇ飼料を与えた。表２に試験食の配合表を示す。各群に、前述の試験食を自由摂取させて約２ヶ月間飼育し、試験開始日より６６日後に剖検を行った。飼育期間中および剖検時に以下の項目について測定を行った。測定結果の統計解析はＥＸＣＥＬを用いたＳｔｕｄｅｎｔのｔ検定で行った。
＜試験期間中測定項目＞
体重、摂餌量および摂水量：試験開始日および試験開始日より１、２、３、６、８、１０、１３、１５、１７、２０、２２、２４、２７、２９、３１、３４、３５、３６、３７、３８、４１、４３、４５、４８、５０、５２、５５、５７、５９、６２、６４、６６日後に測定した。
＜剖検時測定項目＞
剖検時の脂肪量：精巣周囲および後腹膜の脂肪を採取し、その湿重量（ｇ）を測定した。さらに、その値を体重で除して、相対脂肪量（ｇ／ｇ体重）を求めた。

上記表２は試験食９０．２ｇ当たりの配合量（ｇ）を示す。なお、ＡＩＮ−９３Ｇは米国国立栄養研究所（ＡＩＮ）から１９９３年に発表されたマウスやラットにおける栄養研究用の標準精製飼料であり、成長期、妊娠期、授乳期に用いられる標準精製飼料である。
（２）結果および考察
体重および平均摂取熱量：結果を第４図に示す。両群とも体重は順調に増加し、群間に有意な差は認められなかった。試験期間中の平均摂餌量（ｇ／ｂｏｄｙ，ｄａｙ）から以下の式（数式３：４０％ショ糖添加ＡＩＮ−９３Ｇ飼料および４０％パラチノース添加ＡＩＮ−９３Ｇ飼料）により試験期間中の平均摂取熱量（ｋｃａｌ／ｂｏｄｙ，ｄａｙ）を算出したところ、対照群およびパラチノース群でそれぞれ７２．９および６９．９ｋｃａｌ／ｒａｔ／ｄａｙとなり、ほぼ同等であった。

剖検時の相対脂肪量：結果を第５図に示す。精巣周囲および後腹膜の相対脂肪量は、パラチノース群は対照群に比べて有意（ｐ＜０．０１）に低い値を示した。
このように、体重増加および摂取熱量が同等であるにも関わらず、パラチノース群は対照群に比べて脂肪蓄積量が有意に低いことが認められた。マウス・ラット用精製飼料の糖質の一部をパラチノースに置換することによって、体脂肪の蓄積を抑制できることが明らかとなった。
［実施例３］（キシリトールとパラチノースの相乗作用）
（１）材料および方法
Ｃ５７ＢＬ／６マウス（雄性、５週齢入荷、６週齢試験開始、ｎ＝６／群）を群分けしてＸｙ１（−）群とＸｙ１（＋）群を設けた。Ｘｙ１（＋）群には試験食として表３に示す飼料を与えた。また、Ｘｙ１（−）群には表３に示す飼料に含まれるキシリトールをデキストリンに置き換えた、表４に示す飼料を試験食として与えた。各群に、前述の試験食を自由摂取させて約２ヶ月間飼育した後、試験開始日より６０日後に剖検を行った。飼育期間中および剖検時に以下の項目について測定を行った。測定結果の統計解析はＥＸＣＥＬを用いたＳｔｕｄｅｎｔのｔ検定で行った。
＜試験期間中測定項目＞
（Ａ）体重：試験開始日および試験開始日より４、８、１１、１５、１８、２２、２５、２９、３２、３６、３９、４３、４５、４９、５３、５７日後に測定した。
（Ｂ）筋肉量および脂肪量：試験開始前（試験開始日より６日前）、試験中期（試験開始日より２８日後）、試験後期（試験開始日より５６日後）にＸ線ＣＴにより測定した。具体的には、マウスにイソフルレン（フォーレン（登録商標）、大日本製薬株式会社製）を吸入させ麻酔下にて、Ｘ線ＣＴ装置（実験動物用Ｘ線ＣＴラシータ（登録商標）ＬＴ−１００、アロカ株式会社製）を用いて、筋肉量（ｇ）および脂肪（内臓脂肪および皮下脂肪）量（ｇ）を測定した。さらにそれらの値を測定時の体重で除して、相対筋肉量（ｇ／ｇ体重）および相対脂肪量（ｇ／ｇ体重）を求めた。
＜剖検時測定項目＞
脂肪量：精巣周囲、後腹膜および腸間膜の脂肪を採取し、その湿重量（ｇ）を測定した。さらに、その値を体重で除して、相対脂肪量（ｇ／ｇ体重）を求めた。

（２）結果および考察
体重：結果を第６図に示す。体重は両群とも順調に増加したが、試験開始より４３日後以降は、Ｘｙ１（＋）群はＸｙ１（−）群に比較して有意に（ｐ＜０．０５）低い値を認めた。
相対筋肉量および相対脂肪量：結果を第７図に示す。Ｘ線ＣＴの結果から求めた相対筋肉量は試験開始前、試験中期においては、両群に有意な差を認めなかったが、試験後期にＸｙ１（＋）群はＸｙ１（−）群に対して有意に（ｐ＜０．０５）高い値を示した。Ｘ線ＣＴの結果から求めた相対脂肪量は、試験開始前では差がなく、飼育期間の経過にしたがってＸｙ１（＋）群がＸｙ１（−）群に比べて低い値を示す傾向にあった。試験後期では、Ｘｙ１群は対照群に比べて有意に（ｐ＜０．０５）低い値を示した。
剖検時の相対脂肪量：結果を第８図に示す。精巣周囲、後腹膜および腸間膜の相対脂肪量はいずれにおいても、Ｘｙ１（＋）群はＸｙ１（−）群に比べて有意（ｐ＜０．０１：精巣周囲、後腹膜および腸間膜の脂肪量）に低い値を示し、Ｘ線ＣＴ測定と同様の結果が得られた。
以上のように、Ｘｙ１（＋）群はＸｙ１（−）群に比べて体重増加、脂肪蓄積量が有意に低く、筋肉量は有意に高いことが認められた。さらに、実施例１（キシリトール単独）実施例２（パラチノース単独）の例と比較しても、脂肪蓄積抑制効果は顕著であった。このことから、脂肪蓄積抑制に対してキシリトールとパラチノースの相乗効果が大きいものであることが明らかとなった。
［実施例４］（キシリトールおよびパラチノースによる体脂肪蓄積抑制効果の測定）
（１）材料および方法
Ｃ５７ＢＬ／６マウス（雄性、６週齢試験開始）を環境馴化後、体重を指標に各群６匹の６群に分け、表５に示す試験食を各群の動物に自由摂取させ、この日を試験開始日として約２ヶ月間試験食による飼育を行った。動物は試験開始日より５９日後から１晩絶食し、試験開始日より６０日後に剖検を行った。いずれの期間も水は自由摂取とした。飼育期間中および剖検時に以下の項目について測定を行った。測定結果の統計解析には統計ソフトＳｔａｔ Ｌｉｇｈｔ（ユックムス社）を用い、検定はＴｕｋｅｙ−Ｋｒａｍｅｒ ｍｕｌｔｉｐｌｅ ｃｏｍｐａｒｉｓｏｎ ｔｅｓｔにて行った。
＜試験期間中測定項目＞
（Ａ）体重：試験開始日および試験開始日より４、８、１０、１４、１８、２２、２５、２８、３２、３６、３９、４３、４６、５０、５３、５６、５９日後に測定した。摂餌量、摂水量：前記体重測定と同日に残餌および残水量を測定し、摂餌量、摂水量を算出した。
（Ｂ）筋肉量および脂肪量：試験開始前（試験開始日より７又は６日前）、試験中期（試験開始日より２８又は２９日後）、試験後期（試験開始日より５６又は５７日後）にＸ線ＣＴにより測定した。具体的には、マウスにイソフルレン（フォーレン（登録商標）、大日本製薬株式会社製）を吸入させ麻酔下にて、Ｘ線ＣＴ装置（実験動物用Ｘ線ＣＴラシータ（登録商標）ＬＴ−１００、アロカ社製）を用いて、筋肉量（ｇ）および脂肪（内臓脂肪および皮下脂肪）量（ｇ）を測定した。さらにそれらの値を測定時の体重で除して、相対筋肉量（ｇ／ｇ体重）および相対脂肪量（ｇ／ｇ体重）を求めた。
＜剖検時測定項目＞
脂肪量：精巣周囲、後腹膜および腸間膜の脂肪を採取し、その湿重量（ｇ）を測定した。さらに、その値を体重で除して、相対脂肪量（ｇ／ｇ体重）を求めた。
臓器重量：膵臓、肝臓、脾臓、腎臓を摘出し、その湿重量（ｇ）を測定した。さらに、その値を体重で除して、相対臓器重量（ｇ／ｇ体重）を求めた。

群構成および試験食を表５に示す。ここでは各試験食２７．９ｇ当たりの配合量（ｇ）を示す。また、表５に記載の改変ＡＩＮ−９３Ｍとは、米国国立栄養研究所（ＡＩＮ）から１９９３年に発表されたマウスやラットにおける栄養研究用の標準精製飼料であるＡＩＮ−９３Ｍよりコーンスターチおよびショ糖を除いたものをいう。なお、ＡＩＮ−９３Ｍは成長期を過ぎた成熟動物用の標準精製飼料である。いずれの試験食も粉餌の状態である。
（２）結果および考察
体重：結果を第９図に示す。各群ともに体重は順調に増加した。試験開始日より５６日後に併用高用量群と対照群の間に有意な差が認められたが、有意な差が認められたのはこの１日のみであったため、試験期間を通して体重推移に試験食は影響を及ぼさなかったと判断した。
摂餌量：結果を表６に示す。

表６中、各摂取熱量は以下の数式４にて算出した。

試験期間中のマウス１匹あたりの合計摂餌量には各群間に有意な差は認められなかった。また、試験期間中のマウス１匹あたり１日の平均摂餌量、摂餌量および飼料１ｇあたりの熱量から求めた平均摂取熱量についても各群間に有意な差は認められなかった。
筋肉量および脂肪量：結果を第１０図に示す。
第１０図中、右に表示している「１ 対照群」〜「６ 併用高用量群」の順は、グラフの左端の「１ 対照群」から右端の「６ 併用高用量群」までの順に対応している。図１１〜図１３についても同様である。
Ｘ線ＣＴから求めた相対筋肉量には、試験前において各群間に有意な差は認められなかったが、試験中期にキシリトール低用量群（ｐ＜０．０５）、併用低用量群（ｐ＜０．０５）、キシリトール高用量群（ｐ＜０．０５）および併用高用量群（ｐ＜０．０１）が対照群に比較して有意な高値を示した。また、試験後期には併用高用量群（ｐ＜０．０１）が対照群に比較して有意な高値を示した。
Ｘ線ＣＴから求めた相対脂肪量は、試験前において各群間に有意な差は認められなかったが、試験中期にキシリトール低用量群（ｐ＜０．０５）、併用低用量群（ｐ＜０．０５）、キシリトール高用量群（ｐ＜０．０５）および併用高用量群（ｐ＜０．０１）が対照群に比較して有意な低値を示した。また、試験後期には併用高用量群（ｐ＜０．０１）が対照群に比較して有意な低値を示した。
剖検時の相対臓器重量：いずれの臓器も、群間に有意な差を認めなかった。
剖検時の相対脂肪量：結果を第１１図（精巣周囲）、第１２図（腸間膜）、および第１３図（後腹膜）に示す。第１１図に示すように、精巣周囲の相対脂肪量は、対照群と比較して、対照群以外の全群で低値を示し、併用高用量群（ｐ＜０．０５）では有意な差が認められた。
第１２図に示すように、後腹膜の相対脂肪量は、対照群と比較して、対照群以外の全群で低値を示し、併用低用量群（ｐ＜０．０５）、キシリトール高用量群（ｐ＜０．０５）および併用高用量群（ｐ＜０．０１）では有意な差が認められた。
第１３図に示すように、腸間膜の相対脂肪量は、対照群と比較して、対照群以外の全群で低値を示し、併用低用量群（ｐ＜０．０５）および併用高用量群（ｐ＜０．０１）では有意な差が認められた。
以上のように、体重推移、摂取熱量および相対臓器重量において、各群間に差は認められなかった。体重あたりの筋肉量および脂肪量、あるいは剖検時の３種類の脂肪重量において、キシリトールおよび併用群に有意な低値が認められ、パラチノース群に低値傾向が認められた。とりわけ、試験食２７．９ｇ中にパラチノース７．００ｇおよびキシリトール０．９０ｇを含有した併用高用量群においては、試験食２７．９ｇ中にパラチノース７．００ｇおよびキシリトール０．４５ｇを含有した併用低用量群と比較して、パラチノースとキシリトールの相乗効果が顕著にみられた。
本発明の抗脂肪蓄積用組成物は、抗脂肪蓄積効果を有するため、同機能を有する医薬品または飲食品として応用が可能である。EXAMPLES Hereinafter, although an Example is given and this invention is demonstrated, this invention is not limited by this.
[Example 1] (Measurement of antifat accumulation effect of xylitol)
(1) Materials and Methods C57BL / 6 mice (male, 5-week-old arrival, 6-week-old test started, n = 9 / group) were grouped into a control group (hereinafter also referred to as AIN group) and an Xy1 group. It was. The control group received AIN-93M diet as a test meal. In addition, the Xy1 group was given as a test meal xylitol-added AIN-93M feed in which a part of sucrose contained in the AIN-93M feed was replaced with xylitol (hereinafter also referred to as Xy1). In addition, in the xylitol-added AIN-93M feed, the amount of sucrose added for Xy1 was reduced, and the sugar mass in the test meal was made equal to that of the AIN-93M feed. Table 1 shows a recipe for each test meal. Each group was allowed to ingest the above-mentioned test food ad libitum and reared for about 2 months, and then an autopsy was performed 58 days after the test start date. The following items were measured during the breeding period and at necropsy. Statistical analysis of the measurement results was performed by Student's t-test using EXCEL.
<Measurement items during the test period>
(A) Body weight, food intake and water intake: 4, 8, 11, 15, 18, 22, 25, 29, 32, 36, 39, 43, 46, 50, 53 from the test start date and test start date Measurements were taken after 57 days.
(B) Muscle mass and fat mass: Measured by X-ray CT before the start of the test (6 days before the test start date), during the middle of the test (25 days after the test start date), and later in the test (53 days after the test start date). Specifically, the mouse was inhaled with isoflurane (Foren (registered trademark), manufactured by Dainippon Pharmaceutical Co., Ltd.) and under anesthesia, an X-ray CT apparatus (X-ray CT rasita (registered trademark) LT-100 for experimental animals), The amount of muscle (g) and the amount of fat (visceral fat and subcutaneous fat) (g) were measured using Aloka Co., Ltd. Furthermore, those values were divided by the body weight at the time of measurement to determine relative muscle mass (g / g body weight) and relative fat mass (g / g body weight).
<Measurement items at necropsy>
Fat mass: The fat around the testis, retroperitoneum and mesentery was collected, the wet weight (g) was measured, and the value was divided by the body weight to determine the relative fat mass (g / g body weight).

Table 1 shows the blending amount (g) per 100 kcal of each test meal. The modified AIN-93M shown in Table 1 is corn starch and sucrose from AIN-93M, which is a standard purified feed for nutritional research in mice and rats, published in 1993 by the National Institute of Nutrition (AIN). It means the thing except. AIN-93M is a standard refined feed for mature animals after the growth period.
(2) Results and discussion Body weight and average calorie intake: The results are shown in FIG. Body weight increased steadily in both groups, and no significant difference was observed between the groups. From the average food intake (g / body, day) during the test period, the following formula (Formula 1: AIN-93M feed and Formula 2: AIN-93M feed supplemented with xylitol) is used to calculate the average heat intake (kcal / body) during the test period. , Day) were calculated to be 12.7 and 12.3 kcal / body, day in the control group and the Xy1 group, respectively, which were almost the same.

Relative muscle mass and relative fat mass: The results are shown in FIG. There was no difference in the relative muscle mass obtained from the results of X-ray CT before the start of the test, and the Xy1 group tended to show a higher value than the control group as the breeding period progressed. In the late stage of the test, the Xy1 group showed a significantly higher value (p <0.05) than the control group. The relative fat amount obtained from the results of X-ray CT had no difference before the start of the test, and the Xy1 group tended to show a lower value than the control group as the breeding period progressed. In the late stage of the test, the Xy1 group showed a significantly lower value (p <0.05) than the control group.
Relative fat mass at autopsy: The results are shown in FIG. The relative fat mass of the retroperitoneum and mesentery tended to be lower in the Xy1 group than in the control group. The relative fat mass around the testis was significantly lower (p <0.05) in the Xy1 group than in the control group, and the same results as in the X-ray CT measurement were obtained.
As described above, it was recognized that the amount of accumulated fat was significantly lower in the Xy1 group than in the control group, although the weight gain and the calorie intake were equivalent. It became clear that the accumulation of body fat can be suppressed by substituting a part of carbohydrates in purified feed for mice and rats with Xy1.
[Example 2] (Measurement of anti-fat accumulation effect of palatinose)
(1) Materials and Methods SD rats (male, 4-week-old arrival, 6-week-old test start, n = 6 / group) were divided into groups to provide a palatinose group and a control group. AIN-93G from which corn starch and sucrose are removed (hereinafter also referred to as modified AIN-93G) is mixed with 60% (w / w), 40% (w / w) of palatinose, and 40% palatinose added. The group which produced feed and gave this as a test meal was made into the palatinose group. A 40% sucrose-added AIN-93G diet prepared by mixing 60% (w / w) of modified AIN-93G and 40% (w / w) of sucrose was given to the control group. Table 2 shows a recipe for the test meal. Each group was allowed to freely ingest the above-mentioned test food and reared for about 2 months, and an autopsy was performed 66 days after the test start date. The following items were measured during the breeding period and at necropsy. Statistical analysis of the measurement results was performed by Student's t-test using EXCEL.
<Measurement items during the test period>
Body weight, food intake and water intake: 1, 2, 3, 6, 8, 10, 13, 15, 17, 20, 22, 24, 27, 29, 31, 34, 35 from the test start date and test start date 36, 37, 38, 41, 43, 45, 48, 50, 52, 55, 57, 59, 62, 64, 66 days later.
<Measurement items at necropsy>
Fat mass at necropsy: The fat around the testis and retroperitoneum was collected and its wet weight (g) was measured. Further, the value was divided by the body weight to determine the relative fat mass (g / g body weight).

Table 2 above shows the blending amount (g) per 90.2 g of the test meal. AIN-93G is a standard purified feed for nutritional research in mice and rats announced in 1993 by the National Institute of Nutrition (AIN). It is a standard purified feed used during the growth, pregnancy and lactation periods. is there.
(2) Results and discussion Body weight and average calorie intake: The results are shown in FIG. Body weight increased steadily in both groups, and no significant difference was observed between the groups. From the average food intake (g / body, day) during the test period, the following formula (Formula 3: 40% sucrose-added AIN-93G feed and 40% palatinose-added AIN-93G feed) When (kcal / body, day) was calculated, it was 72.9 and 69.9 kcal / rat / day in the control group and palatinose group, respectively, which were almost the same.

Relative fat mass at autopsy: The results are shown in FIG. The relative fat mass around the testis and retroperitoneum was significantly lower in the palatinose group than in the control group (p <0.01).
As described above, it was observed that the amount of accumulated fat was significantly lower in the palatinose group than in the control group, although the weight gain and the calorie intake were equivalent. It became clear that the accumulation of body fat can be suppressed by substituting part of the carbohydrate of purified feed for mice and rats with palatinose.
[Example 3] (Synergistic action of xylitol and palatinose)
(1) Materials and Methods C57BL / 6 mice (male, 5-week-old arrival, 6-week-old test started, n = 6 / group) were grouped to provide an Xy1 (−) group and an Xy1 (+) group. The feed shown in Table 3 was given to the Xy1 (+) group as a test meal. The Xy1 (−) group was fed with the feed shown in Table 4 in which xylitol contained in the feed shown in Table 3 was replaced with dextrin as a test meal. Each group was allowed to freely take the above-mentioned test food and reared for about 2 months, and then an autopsy was performed 60 days after the test start date. The following items were measured during the breeding period and at necropsy. Statistical analysis of the measurement results was performed by Student's t-test using EXCEL.
<Measurement items during the test period>
(A) Body weight: measured on the test start date and 4, 8, 11, 15, 18, 22, 25, 29, 32, 36, 39, 43, 45, 49, 53, 57 days after the test start date.
(B) Muscle mass and fat mass: Measured by X-ray CT before the start of the test (6 days before the test start date), during the middle of the test (28 days after the test start date), and during the late test (56 days after the test start date). Specifically, the mouse was inhaled with isoflurane (Foren (registered trademark), manufactured by Dainippon Pharmaceutical Co., Ltd.) and under anesthesia, an X-ray CT apparatus (X-ray CT rasita (registered trademark) LT-100 for experimental animals), The amount of muscle (g) and the amount of fat (visceral fat and subcutaneous fat) (g) were measured using Aloka Co., Ltd. Furthermore, those values were divided by the body weight at the time of measurement to determine relative muscle mass (g / g body weight) and relative fat mass (g / g body weight).
<Measurement items at necropsy>
Fat content: Fat around the testis, retroperitoneum and mesentery was collected and its wet weight (g) was measured. Further, the value was divided by the body weight to determine the relative fat mass (g / g body weight).

(2) Results and discussion Body weight: The results are shown in FIG. The body weight increased smoothly in both groups, but after 43 days from the start of the test, the Xy1 (+) group showed a significantly lower value (p <0.05) than the Xy1 (−) group.
Relative muscle mass and relative fat mass: the results are shown in FIG. The relative muscle mass determined from the results of X-ray CT showed no significant difference between the two groups before the start of the test and in the middle of the test, but the Xy1 (+) group compared to the Xy1 (−) group in the latter half of the test. Significantly (p <0.05) higher values. The relative fat amount obtained from the results of X-ray CT had no difference before the start of the test, and the Xy1 (+) group tended to show a lower value than the Xy1 (−) group as the breeding period progressed. In the late stage of the test, the Xy1 group showed a significantly lower value (p <0.05) than the control group.
Relative fat mass at autopsy: The results are shown in FIG. The relative fat mass of the testicle, retroperitoneum, and mesentery was significantly higher in the Xy1 (+) group than in the Xy1 (−) group (p <0.01: testicular, retroperitoneum, and mesentery). (Fat mass) showed a low value, and the same result as the X-ray CT measurement was obtained.
As described above, it was confirmed that the Xy1 (+) group had significantly lower body weight gain and fat accumulation and the muscle mass was significantly higher than the Xy1 (−) group. Furthermore, the effect of suppressing fat accumulation was remarkable even when compared with the example of Example 1 (xylitol alone) and Example 2 (palatinose alone). From this, it was revealed that the synergistic effect of xylitol and palatinose is great for suppressing fat accumulation.
[Example 4] (Measurement of body fat accumulation inhibitory effect by xylitol and palatinose)
(1) Materials and Methods C57BL / 6 mice (male, 6-week-old test start) were acclimated to the environment, then divided into 6 groups of 6 animals in each group using body weight as an index, and the test diet shown in Table 5 was assigned to each group of animals. It was allowed to ingest freely, and this day was used as a test start date for breeding with a test meal for about two months. The animals were fasted overnight from 59 days after the start of the study, and necropsied 60 days after the start of the study. In all periods, water was ad libitum. The following items were measured during the breeding period and at necropsy. Statistical analysis of the measurement results was performed using statistical software Stat Light (Yukmus), and the test was performed using the Tukey-Kramer multiple comparison test.
<Measurement items during the test period>
(A) Body weight: measured on the test start date and 4, 8, 10, 14, 18, 22, 25, 28, 32, 36, 39, 43, 46, 50, 53, 56, 59 days after the test start date . Food intake and water consumption: The amount of food remaining and the amount of water remaining were measured on the same day as the body weight measurement, and the amount of food intake and the amount of water intake were calculated.
(B) Muscle mass and fat mass: X before the start of the test (7 or 6 days before the start date of the test), mid-term (28 or 29 days after the start date of the test), late in the test (56 or 57 days after the start date of the test) Measured by line CT. Specifically, the mouse was inhaled with isoflurane (Foren (registered trademark), manufactured by Dainippon Pharmaceutical Co., Ltd.) and under anesthesia, an X-ray CT apparatus (X-ray CT rasita (registered trademark) LT-100 for experimental animals), The amount of muscle (g) and the amount of fat (visceral fat and subcutaneous fat) (g) were measured using Aloka. Furthermore, those values were divided by the body weight at the time of measurement to determine relative muscle mass (g / g body weight) and relative fat mass (g / g body weight).
<Measurement items at necropsy>
Fat content: Fat around the testis, retroperitoneum and mesentery was collected and its wet weight (g) was measured. Further, the value was divided by the body weight to determine the relative fat mass (g / g body weight).
Organ weight: The pancreas, liver, spleen and kidney were removed and their wet weight (g) was measured. Further, the value was divided by the body weight to obtain the relative organ weight (g / g body weight).

Table 5 shows the group composition and test meal. Here, the blending amount (g) per 27.9 g of each test meal is shown. The modified AIN-93M shown in Table 5 is corn starch and sucrose from AIN-93M, which is a standard purified feed for nutritional research in mice and rats, published in 1993 by the National Institute of Nutrition (AIN). It means the thing except. AIN-93M is a standard refined feed for mature animals after the growth period. All the test meals are in a powdered state.
(2) Results and discussion Body weight: The results are shown in FIG. Body weight increased steadily in each group. A significant difference was found between the combined high-dose group and the control group 56 days after the start of the study, but only this one day showed a significant difference. The food was judged to have no effect.
Food intake: The results are shown in Table 6.

In Table 6, each intake calorie was calculated by the following mathematical formula 4.

There was no significant difference between the groups in the total food consumption per mouse during the study period. In addition, no significant difference was found between the groups in terms of the average daily food intake per mouse during the test period, the average food intake, and the average heat intake determined from the amount of heat per gram of feed.
Muscle mass and fat mass: the results are shown in FIG.
In FIG. 10, the order of “1 control group” to “6 combination high dose group” displayed on the right is the order from “1 control group” on the left end of the graph to “6 combination high dose group” on the right end. It corresponds. The same applies to FIGS. 11 to 13.
There was no significant difference between the groups in the relative muscle mass determined from the X-ray CT, but the xylitol low dose group (p <0.05) and the combination low dose group (p <0.05), the xylitol high dose group (p <0.05) and the combination high dose group (p <0.01) showed significantly higher values than the control group. Further, in the latter period of the test, the combination high dose group (p <0.01) showed a significantly higher value than the control group.
The relative fat amount determined from X-ray CT did not show a significant difference between the groups before the test, but in the middle period of the test, the xylitol low dose group (p <0.05) and the combination low dose group (p < 0.05), the xylitol high dose group (p <0.05) and the combination high dose group (p <0.01) showed significantly lower values than the control group. Further, in the latter period of the test, the combination high dose group (p <0.01) showed a significantly lower value than the control group.
Relative organ weight at necropsy: No significant differences were found between groups in any organ.
Relative fat mass at necropsy: The results are shown in FIG. 11 (peripheral testis), FIG. 12 (mesentery), and FIG. 13 (retroperitoneum). As shown in FIG. 11, the relative fat mass around the testis was lower in all groups except the control group than in the control group, and was significantly different in the combined high dose group (p <0.05). Was recognized.
As shown in FIG. 12, the relative fat amount of the retroperitoneum showed a low value in all groups other than the control group as compared with the control group, the combination low dose group (p <0.05), and the high dose of xylitol. There was a significant difference between the group (p <0.05) and the combination high dose group (p <0.01).
As shown in FIG. 13, the relative fat mass of the mesentery showed a low value in all groups except the control group compared to the control group, the combination low dose group (p <0.05) and the combination high Significant differences were observed in the dose group (p <0.01).
As described above, there was no difference between the groups in the body weight transition, intake calorie, and relative organ weight. Significantly low values were observed in the xylitol and combination groups, and a trend toward low values was observed in the palatinose group in muscle mass and fat mass per body weight, or three types of fat weights at necropsy. In particular, in the combined high dose group containing 7.00 g of palatinose and 0.90 g of xylitol in 27.9 g of the test meal, the combined low dose containing 7.00 g of palatinose and 0.45 g of xylitol in the test meal of 27.9 g Compared with the group, the synergistic effect of palatinose and xylitol was noticeable.
Since the anti-fat accumulation composition of the present invention has an anti-fat accumulation effect, it can be applied as a pharmaceutical or a food or drink having the same function.

Claims (11)

An anti-fat accumulating composition containing a sugar alcohol. The composition for accumulating anti-fat according to claim 1, comprising an oligosaccharide. The composition for accumulating anti-fat according to claim 2, wherein the oligosaccharide is a hetero-oligosaccharide, The composition for anti-fat accumulation according to claim 3, wherein the hetero-oligosaccharide is a sucrose structural isomer, The composition for anti-fat accumulation according to any one of claims 2 to 4, wherein the sucrose structural isomer is palatinose. The composition for accumulating anti-fat according to any one of claims 2 to 5, comprising the sugar alcohol and the oligosaccharide in a weight ratio of 1: 3 to 1:20. The composition for accumulating anti-fat according to any one of claims 1 to 6, wherein the sugar alcohol is xylitol. A pharmaceutical product for preventing and / or treating fat accumulation, comprising as an active ingredient the composition for anti-fat accumulation according to any one of claims 1 to 7. A food and drink for preventing and / or treating fat accumulation, comprising the antifat accumulation composition according to any one of claims 1 to 7. The composition for anti-fat accumulation according to any one of claims 1 to 7 for producing a drug for preventing and / or treating fat accumulation or a food or drink for preventing and / or treating fat accumulation. Use of. A method for preventing and / or treating fat accumulation, comprising administering the anti-fat accumulation composition according to any one of claims 1 to 7.

Images